Search results
Results from the WOW.Com Content Network
Regenerative Medicine is a peer-reviewed medical journal covering stem cell research and regenerative medicine. It was established in 2006 and is published by Future Medicine. The editor-in-chief is Chris Mason (University College London). Regenerative Medicine has an online sister community site called RegMedNet. RegMedNet is a free-to-join ...
The Journal of Stem Cells & Regenerative Medicine is an open-access online scientific journal.It is the official journal of the German Society for Stem Cell Research (GSZ) and publishes research articles focusing on stem cells and regenerative medicine and related fields.
In March 2000, Haseltine, Antony Atala, M.D., Michael D. West, Ph.D., and other leading researchers founded E-Biomed: The Journal of Regenerative Medicine. [25] The peer-reviewed journal facilitated discourse around regenerative medicine by publishing innovative research on stem cell therapies, gene therapies, tissue engineering, and ...
A major technology of regenerative medicine is tissue engineering, [2] which has variously been defined as "an interdisciplinary field that applies the principles of engineering and the life sciences toward the development of biological substitutes that restore, maintain, or improve tissue function", or "the creation of new tissue by the ...
Regenerative Medicine (journal) S. Stem Cell Reports; Stem Cell Reviews and Reports This page was last edited on 5 October 2016, at 08:14 (UTC). Text is ...
The study, published in the journal Cell Stem Cell, involved targeting a certain set of genes used in reproduction in order to create what are called bipaternal offspring, with two biologically ...
Cell Transplantation is a monthly peer-reviewed medical journal covering regenerative medicine.It was established in 1992 and was originally published by Cognizant Communication Corporation until 2017, when it was acquired by SAGE Publications. [1]
NEW YORK, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress of the U.S. commercial launch of Ryoncil ® (remestemcel-L) for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients 2 months and older and key upcoming milestones ...